Barbara J Mintzes (Barbara Mintzes)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 38

Top Venues

Drug and therapeutics bulletin

BMJ open

BMJ (Clinical research ed.)

The Medical journal of Australia

University of Sydney

University of British Columbia (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Sydney Apr 01 2015

Australia

Associate Professor :: School of Pharmacy and Charles Perkins Centre

Education History

University of British Columbia Sep 01 1997 - Jun 01 2003

Canada

PHD :: Department of Health Care & Epidemiology

Publications

Barbara J Mintzes
Do regulatory safety warnings on medicines miss the mark? Drug and therapeutics bulletin 62 (4) (2024)
Malcolm Peter Forbes, Yeshna Bhowon, Barbara J Mintzes
Pharmaceutical company payments to Australian doctors reported to Medicines Australia, 2019-22: a cross-sectional analysis. The Medical journal of Australia (2024)
Barbara J Mintzes
Do regulatory safety warnings on medicines miss the mark? Drug and therapeutics bulletin 62 (4) (2024)
David Benjamin Menkes, Barbara J Mintzes, Joel R Lexchin
Direct-to-consumer advertising: a modifiable driver of overdiagnosis and overtreatment. BMJ evidence-based medicine (2024)
Malcolm Peter Forbes, Yeshna Bhowon, Barbara J Mintzes
Pharmaceutical company payments to Australian doctors reported to Medicines Australia, 2019-22: a cross-sectional analysis. The Medical journal of Australia 220 (8) (2024)
Malcolm Peter Forbes, Yeshna Bhowon, Barbara J Mintzes
Pharmaceutical company payments to Australian doctors reported to Medicines Australia, 2019-22: a cross-sectional analysis. The Medical journal of Australia 220 (8) (2024)
Barbara J Mintzes
Do regulatory safety warnings on medicines miss the mark? Drug and therapeutics bulletin (2024)
Joel R Lexchin, Barbara J Mintzes
Semaglutide: a new drug for the treatment of obesity. Drug and therapeutics bulletin (2023)
Ashleigh Hooimeyer, Travis Lines, Janet Mirzaei, Preshita Pande, Sylviya Ganeshamoorthy, Alice Fabbri, Lisa M Parker, Adam G Dunn, Barbara J Mintzes
Conflict of Interest Policies at Australian Medical Schools. Internal medicine journal (2023)
Barbara J Mintzes, David B Menkes
Pharmaceutical company sponsorship of doctors: is gender equity a concern? The Medical journal of Australia (2023)
Richard L Morrow, Barbara J Mintzes, Garry Gray, Michael R Law, Scott R Garrison, Colin R Dormuth
Public reporting of clinical trial findings as an ethical responsibility to participants: a qualitative study. BMJ open 13 (3) (2023)
Adrian M J Pokorny, Lisa A Bero, Peter Fox, Deme J Karikios, Eliza J McEwin, Ray Moynihan, Barbara J Mintzes
Interactions between Australian cancer physicians and the pharmaceutical industry: a qualitative study. BMJ open 13 (5) (2023)
Courtney Davis, Anita Katharina Wagner, Maximilian Salcher-Konrad, Henry Scowcroft, Barbara J Mintzes, Adrian M J Pokorny, Jianhui Lew, Huseyin Naci
Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe. BMJ (Clinical research ed.) 380 (2023)
Courtney Davis, Anita Katharina Wagner, Maximilian Salcher-Konrad, Henry Scowcroft, Barbara J Mintzes, Adrian M J Pokorny, Jianhui Lew, Huseyin Naci
Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe. BMJ (Clinical research ed.) 380 (2023)
Richard L Morrow, Barbara J Mintzes, Garry Gray, Michael R Law, Scott R Garrison, Colin R Dormuth
Public reporting of clinical trial findings as an ethical responsibility to participants: a qualitative study. BMJ open 13 (3) (2023)
Courtney Davis, Anita Katharina Wagner, Maximilian Salcher-Konrad, Henry Scowcroft, Barbara J Mintzes, Adrian M J Pokorny, Jianhui Lew, Huseyin Naci
Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe. BMJ (Clinical research ed.) 380 (2023)
Richard L Morrow, Barbara J Mintzes, Garry Gray, Michael R Law, Scott R Garrison, Colin R Dormuth
Public reporting of clinical trial findings as an ethical responsibility to participants: a qualitative study. BMJ open 13 (3) (2023)
Anna Kemp-Casey, Barbara J Mintzes, Richard L Morrow, Colin R Dormuth, Patrick C Souverein, Elizabeth E Roughead
Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study. Pharmacoepidemiology and drug safety 31 (10) (2022)
Adrian M J Pokorny, Ray Moynihan, Peter Fox, Deme J Karikios, Lisa A Bero, Barbara J Mintzes
Australian Cancer Physicians and the Pharmaceutical Industry: A Survey of Attitudes and Interactions. JCO oncology practice 18 (7) (2022)
Richard L Morrow, Barbara J Mintzes, Patrick C Souverein, Marie L De Bruin, Elizabeth Ellen Roughead, Joel Lexchin, Anna Kemp-Casey, Lorri Puil, Ingrid Sketris, Dee Mangin, Christine Erikstrup Hallgreen, Sallie-Anne Pearson, Ruth Lopert, Lisa Bero, Richard Ofori-Asenso, Danijela Gnjidic, Ameet Sarpatwari, Lucy T Perry, Colin R Dormuth
Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis. BMJ quality & safety 31 (3) (2022)
Barbara J Mintzes, Ellen Reynolds, Priya Bahri, Lucy T Perry, Alice L Bhasale, Richard L Morrow, Colin R Dormuth
How do safety warnings on medicines affect prescribing? Expert opinion on drug safety 21 (10) (2022)
Barbara J Mintzes, Agnes Vitry
Australia to lose agency dedicated to better quality medicine use. Drug and therapeutics bulletin (2022)
Lorelie Flood, Barbara J Mintzes, Kellia Chiu, Zhaoli Dai, Emily A Karanges, Bennett Holman
Australian Clinical Trial Authors' Declarations of Industry Ties. Journal of general internal medicine 37 (12) (2022)
Barbara J Mintzes, Agnes Vitry
'Drugs to avoid': can we improve prescribing appropriateness? Drug and therapeutics bulletin 59 (11) (2022)
Alice L Bhasale, Ameet Sarpatwari, Wendy Lipworth, Mathias Møllebaek, Eliza J McEwin, Nileesa Gautam, Adrian Santiago Ortiz, Barbara J Mintzes
Regulatory authority and clinical acceptability: Physicians' responses to regulatory drug safety warnings. British journal of clinical pharmacology (2021)
Lisa M Parker, Quinn Grundy, Alice Fabbri, Barbara J Mintzes, Lisa A Bero
'Lines in the sand': an Australian qualitative study of patient group practices to promote independence from pharmaceutical industry funders. BMJ open 11 (2) (2021)
Akash Sharma, Nguyen Tran Minh Duc, Luu Lam Thang Tai, Nguyen Hai Nam, Sze Jia Ng, Kirellos Said Abbas, Nguyen Tien Huy, Ana Marusic, Christine L Paul, Janette S Y Kwok, Juntra Karbwang, Chiara de Waure, Frances J Drummond, Yoshiyuki Kizawa, Erik Taal, Joeri Vermeulen, Gillian Hiu Man Lee, Adam Gyedu, Kien Gia To, Martin L Verra, Évelyne M Jacqz-Aigrain, Wouter K G Leclercq, Simo T Salminen, Cathy Donald Sherbourne, Barbara J Mintzes, Sergi Lozano, Ulrich S Tran, Mitsuaki Matsui, Mohammad Karamouzian
A Consensus-Based Checklist for Reporting of Survey Studies (CROSS). Journal of general internal medicine 36 (10) (2021)
Barbara J Mintzes, Alice L Bhasale, Marc Torka, Ruth Lopert, Sallie-Anne Pearson, Joel R Lexchin, Lisa A Bero
A sorry tale of unnecessary secrecy about medicine safety. Internal medicine journal 51 (10) (2021)
Barbara J Mintzes, Leonore Tiefer, Lisa Cosgrove
Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent. Drug and therapeutics bulletin 59 (12) (2021)
Ashleigh Hooimeyer, Alice L Bhasale, Lucy T Perry, Alice Fabbri, Annim Mohammad, Eliza McEwin, Barbara J Mintzes
Regulatory post-market drug safety advisories on cardiac harm: A comparison of four national regulatory agencies. Pharmacology research & perspectives 8 (6) (2021)
Lucy T Perry, Alice L Bhasale, Alice Fabbri, Joel R Lexchin, Lorri Puil, Maisah Joarder, Barbara J Mintzes
A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States - 2007 to 2016. Pharmacoepidemiology and drug safety 29 (9) (2020)
Alice L Bhasale, Ameet Sarpatwari, Marie Louise De Bruin, Joel R Lexchin, Ruth Lopert, Priya Bahri, Barbara J Mintzes
Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States. Clinical pharmacology and therapeutics 109 (6) (2020)
Alice Fabbri, Lisa Parker, Cinzia Colombo, Paola Mosconi, Giussy Barbara, Maria Pina Frattaruolo, Edith Lau, Cynthia M Kroeger, Carole Lunny, Douglas M Salzwedel, Barbara J Mintzes
Industry funding of patient and health consumer organisations: systematic review with meta-analysis. BMJ (Clinical research ed.) 368 (2020)
Barbara J Mintzes, Joel Lexchin
The "Nuts and Bolts" of Opioid Marketing: Promotional Messages to Family Doctors in Sacramento, Vancouver, Montreal, and Toulouse. Journal of general internal medicine 35 (12) (2020)
Christian-Guy Coichard, Gabriel Perraud, Anne Chailleu, Véronique Gaillac, Paul Scheffer, Barbara J Mintzes
Inadequate conflict of interest policies at most French teaching hospitals: A survey and website analysis. PloS one 14 (11) (2019)
Lisa M Parker, Alice Fabbri, Quinn Grundy, Barbara J Mintzes, Lisa A Bero
"Asset exchange"-interactions between patient groups and pharmaceutical industry: Australian qualitative study. BMJ (Clinical research ed.) 367 (2019)
Marc Torka, Barbara J Mintzes, Alice Bhasale, Alice Fabbri, Lucy Perry, Joel Lexchin
Secret safety warnings on medicines: A case study of information access requests. Pharmacoepidemiology and drug safety 28 (4) (2019)
Teresa Leonardo Alves, Joel R Lexchin, Barbara J Mintzes
Medicines Information and the Regulation of the Promotion of Pharmaceuticals. Science and engineering ethics 25 (4) (2018)

Barbara J Mintzes.css-eqlu8i{font-size:small;padding-left:4px;} (Barbara Mintzes)

Publication Activity (10 Years)

Top Topics

Top Venues

Barbara J Mintzes (Barbara Mintzes)